InsiderTrades.com logo
AI breakthrough about to upend industry
From Porter & Company   |   Ad
Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.
I urge you to watch it now.
Joshua M. Fine net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Joshua Fine Biography and Net Worth

CFO of Cyclo Therapeutics
Mr. Fine was appointed our Chief Financial officer in June 2019 and brings more than 15 years of operational, investment banking and investing experience in Pharmaceutical and Biotechnology sectors.  Josh brings to Cyclo financial expertise and an in-depth understanding of public company accounting.

Mr. Fine also brings significant experience in mergers and acquisitions, business development and strategy development.  Josh served as Senior Vice President of Finance and Operations at Icagen, where as part of the management team he worked on two transformational acquisitions.  After acquiring assets and talent out of Sanofi and Pfizer, Josh worked to transition both operating teams into financial and operational alignment.  While at Icagen, Josh worked closely with the CEO to successfully negotiate and sign multiple licensing deals with Roche, Sanofi, and the Cystic Fibrosis Foundation.  Additionally, Josh was part of the team that led to the strategic sale of Icagen to Ligand in April of 2020.

Prior to joining Icagen Mr. Fine was an investment banking professional focused in the Life Science and Healthcare sectors.  In this role Josh was a part of or led, financings, strategic partnerships, mergers and acquisitions and advisory work.

What is Joshua M. Fine's net worth?

The estimated net worth of Joshua M. Fine is at least $10,647.00 as of March 29th, 2021. Mr. Fine owns 16,900 shares of Cyclo Therapeutics stock worth more than $10,647 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Fine may own. Additionally, Mr. Fine receives a salary of $421,170.00 as CFO at Cyclo Therapeutics. Learn More about Joshua M. Fine's net worth.

How old is Joshua M. Fine?

Mr. Fine is currently 42 years old. There are 3 older executives and no younger executives at Cyclo Therapeutics. The oldest executive at Cyclo Therapeutics is Mr. C. E Strattan, Founder & Director, who is 78 years old. Learn More on Joshua M. Fine's age.

What is Joshua M. Fine's salary?

As the CFO of Cyclo Therapeutics, Inc., Mr. Fine earns $421,170.00 per year. There are 2 executives that earn more than Mr. Fine. The highest earning executive at Cyclo Therapeutics is Mr. N. Scott Fine, CEO & Director, who commands a salary of $569,920.00 per year. Learn More on Joshua M. Fine's salary.

How do I contact Joshua M. Fine?

The corporate mailing address for Mr. Fine and other Cyclo Therapeutics executives is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. Cyclo Therapeutics can also be reached via phone at (386) 418-8060 and via email at [email protected]. Learn More on Joshua M. Fine's contact information.

Has Joshua M. Fine been buying or selling shares of Cyclo Therapeutics?

Joshua M. Fine has not been actively trading shares of Cyclo Therapeutics over the course of the past ninety days. Most recently, on Monday, March 29th, Joshua M. Fine bought 50 shares of Cyclo Therapeutics stock. The stock was acquired at an average cost of $7.40 per share, with a total value of $370.00. Following the completion of the transaction, the chief financial officer now directly owns 16,900 shares of the company's stock, valued at $125,060. Learn More on Joshua M. Fine's trading history.

Who are Cyclo Therapeutics' active insiders?

Cyclo Therapeutics' insider roster includes Joshua Fine (CFO), N. Fine (CEO), Sharon Hrynkow (Insider), Francis Ostronic (Director), Markus Sieger (Director), and Jeffrey Tate (COO). Learn More on Cyclo Therapeutics' active insiders.

Joshua M. Fine Insider Trading History at Cyclo Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/29/2021Buy50$7.40$370.0016,900View SEC Filing Icon  
See Full Table

Joshua M. Fine Buying and Selling Activity at Cyclo Therapeutics

This chart shows Joshua M Fine's buying and selling at Cyclo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclo Therapeutics Company Overview

Cyclo Therapeutics logo
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
Read More

Today's Range

Now: $0.63
Low: $0.60
High: $0.63

50 Day Range

MA: $0.70
Low: $0.57
High: $0.81

2 Week Range

Now: $0.63
Low: $0.57
High: $2.12

Volume

26,548 shs

Average Volume

66,084 shs

Market Capitalization

$18.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
AI breakthrough about to upend industry
From Porter & Company   |   Ad
Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.
I urge you to watch it now.